Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) Gross Margin (2022 - 2025)

TriSalus Life Sciences' Gross Margin history spans 4 years, with the latest figure at 86.66% for Q4 2025.

  • For Q4 2025, Gross Margin rose 138.0% year-over-year to 86.66%; the TTM value through Dec 2025 reached 84.57%, down 148.0%, while the annual FY2025 figure was 84.57%, 148.0% down from the prior year.
  • Gross Margin reached 86.66% in Q4 2025 per TLSIW's latest filing, up from 83.52% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 89.83% in Q4 2023 to a low of 74.71% in Q4 2022.
  • Average Gross Margin over 4 years is 84.17%, with a median of 84.45% recorded in 2024.
  • Peak YoY movement for Gross Margin: surged 1512bps in 2023, then tumbled -455bps in 2024.
  • A 4-year view of Gross Margin shows it stood at 74.71% in 2022, then increased by 20bps to 89.83% in 2023, then fell by -5bps to 85.28% in 2024, then rose by 2bps to 86.66% in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Gross Margin are 86.66% (Q4 2025), 83.52% (Q3 2025), and 83.93% (Q2 2025).